ClinicalTrials.gg
CompletedNCT05505955Updated Oct 23, 2024

Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency

A Phase 1 interventional study of HRS-5965 and Placebo in Glomerulonephritis, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Glomerulonephritis with a site in China — 7 open to participants now, 12 under way, 5 of them phase 3. Glomerulonephritis · China.

Enrollment
8th of 18
83 · median 74
Started
2022
with 3 others
Phase 1
2 of 24
none open now
Registered
13th of 24
by date
Lead sponsor
1 of 24
Chengdu Suncadia Medicine Co., Ltd.

Among the 24 studies in Glomerulonephritis with a site in China, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2022, is one of 2 in phase 1, and was the 13th registered.

Glomerulonephritis

115 studies on the registry are indexed under Glomerulonephritis; 32 are open to participants now.

Browse Glomerulonephritis studies →

Open to participants now

7 of the 24 studies in Glomerulonephritis with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 26 Glomerulonephritis studies recruiting now, 15 (58%) set no upper age limit and 6 (23%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Glomerulonephritis with a site in China, or all of them as a file.
02

Study summary

The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function. The study was divided into three parts:

Part 1: single ascending dose, randomized, double-blind study,with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions; Part 2: Multiple ascending dose, randomized, double-blind study,with 4 dose groups preset; Part 3: an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function.

03

Conditions studied

  • Glomerulonephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects study
  1. Healthy male or female, age ≥ 18 years old and ≤ 70 years old (on the day of signing the );
  2. 18.5kg/m2 ≤\<30 kg/m2, and the weight of men should be ≥ 50kg, and that of women should be ≥ 45kg.

Study on subjects with renal insufficiency

  1. Age ≥ 18 years old and ≤ 70 years old (on the day of signing the informed consent), both men and women can;
  2. 18.5kg/m2≤BMI\<30 kg/m2;
  3. The estimated of subjects with chronic renal insufficiency conforms to 15 ≤ EGFR \< 30 ml/min/1.73m2 (calculated according to CKD-EPI formula, see Appendix 2 of the scheme).

Exclusion criteria

Exclusion Criteria:

  • Healthy subjects study
  1. The researcher has determined that there may be diseases or medical conditions that affect the absorption, distribution, metabolism and excretion of drugs or reduce compliance;
  2. The estimated conforms to EGFR \< 90 ml/min/1.73m2 (calculated according to CKD-EPI formula, see Appendix 2 of the scheme);
  3. According to the judgment of the researcher, any physiological or psychological disease or condition that may increase the risk of the test, affect the subject's compliance with the protocol, or affect the subject's completion of the test.

Study on subjects with renal insufficiency

  1. Those who received renal replacement therapy within 12 weeks before screening; Or the two tests in the screening period indicate that the renal function is unstable (the results in the screening period meet the diagnostic criteria of 2012 KDIGO acute renal injury, or the changes that do not meet the above criteria but are judged to be by the researcher. If there are reasonable reasons, the third test is allowed, and the interval between two consecutive tests should be more than 3 days but not more than 7 days);
  2. According to the judgment of the researcher, the subject has any of the following: in the state of progression or prognosis of disease (including primary renal disease, complications and other complications); The treatment plan needs to be adjusted at any time; Any physical or mental disease or condition that may increase the risk of the test, affect the subject's compliance with the protocol, or affect the subject's completion of the test.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Part 1

    single ascending dose, randomized, double-blind study,with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions. The food impact study consisted of 10 subjects, 8 of whom received HRS-5965 tablets and 2 of whom received placebo. The remaining cohorts required 8 subjects each, with 6 receiving HRS-5965 tablets and 2 receiving placebo.

    Drug: HRS-5965 · Drug: Placebo

  • Experimental
    Part 2

    Multiple ascending dose, randomized, double-blind study,with 4 dose groups preset; Each dose group consisted of 8 healthy adult subjects randomly assigned 6:2 to HRS-5965 tablets or placebo.

    Drug: HRS-5965 · Drug: Placebo

  • Experimental
    Part 3

    an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function. Subjects took HRS5965 tablets.

    Drug: HRS-5965

Interventions

  • Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.

  • DrugPlacebo

    Subjects took Placebo in Part 1 and Part 2.

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events to assess safety and tolerability

    Time frame: up to 24 days

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC) on Day 1 for Part 1 and Part 3

    Time frame: Pre-dose to 144 hours post-dose

  2. Peak plasma concentration (Cmax) on Day 1 for Part 1 and Part 3

    Time frame: Pre-dose to 144 hours post-dose

  3. Time to maximum plasma concentration (Tmax) on Day 1 for Part 1 and Part 3

    Time frame: Pre-dose to 144 hours post-dose

  4. • Area under the plasma concentration versus time curve (AUC) on Day 1 and Day 10 for Part 2

    Time frame: Pre-dose to 144 hours post-dose

  5. Peak plasma concentration (Cmax) on Day 1 and Day 10 for Part 2

    Time frame: Pre-dose to 144 hours post-dose

  6. Time to maximum plasma concentration (Tmax) on Day 1 and Day 10 for Part 2

    Time frame: Pre-dose to 144 hours post-dose

07

Study locations

1 site
  • The Affiliated hospital of QingDao University
    Qingdao, Shandong 266000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Nov 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2022
First posted
Aug 18, 2022
StartActual
Oct 8, 2022
Primary completionActual
Nov 3, 2023
CompletionActual
Nov 3, 2023
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05505955
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Oct 8, 2022
Primary completion
Nov 3, 2023
Completion
Nov 3, 2023
Last update
Oct 23, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5965

Start the discussion